Hubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan, 430062, China.
Hubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan, 430062, China.
J Ethnopharmacol. 2023 Feb 10;302(Pt A):115896. doi: 10.1016/j.jep.2022.115896. Epub 2022 Nov 2.
Salvia miltiorrhiza (the roots of S. miltiorrhiza Bunge, Danshen in Chinese), a traditional Chinese medicine, has been clinically used to prevent and treat various diseases, such as cardiovascular and cerebrovascular diseases, diabetes, and hepatitis B, in China and some other Asian countries. Lithospermic acid (LA), a polyphenol derived from S. miltiorrhiza, has been reported to exhibit multiple pharmacological properties, such as anti-inflammatory, anti-HIV, and anti-carbon tetrachloride-induced liver injury activities. However, little is known about the anti-hepatitis B virus (HBV) activity of LA.
The study was projected to investigate the anti-HBV activity of LA in vitro (HepG2.2.15 and pHBV1.3-transfected HepG2 cells) and in vivo (pAAV-HBV1.2 hydrodynamic injection [HBV-HDI] mice) and explore the potential mechanism as well.
Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) contents were detected by ELISA kits. HBV DNA and hepatitis B core antigen (HBcAg) levels were evaluated by quantitative real-time polymerase chain reaction and immunohistochemistry assay, respectively. The proteins in autophagy process, lysosomal acidic function, and autophagy-related signaling pathways were examined by Western blot. Transmission electron microscopy was used to observe the number of autophagosomes and autolysosomes. Confocal microscopy was applied to analyze the autophagic flux and lysosomal acidification, using mCherry-enhanced green fluorescent protein (EGFP)-microtubule-associated protein light chain (LC)3 and lysosomal probes, respectively.
LA exhibited anti-HBV activity by inhibiting HBV DNA replication in HepG2.2.15 and pHBV-transfected HepG2 cells in dose- and time-dependent manners and hampering HBsAg and HBeAg levels in HepG2.2.15 cells to a certain extent. LA reduced HBV DNA, HBsAg/HBeAg, and HBcAg levels in the serum/liver tissues of HBV-HDI C57BL/6 mice during the 3-week treatment and suppressed the withdrawal rebound of HBV DNA and HBsAg in the mice serum. LA increased LC3-II protein expression and the number of autolysosomes/autophagosomes and promoted the degradation of sequestosome 1(p62) protein in vitro and in vivo. LA enhanced the co-localization of LC3 protein with autolysosomes, further confirming the ability of LA to induce a complete autophagy. Knockdown of autophagy-related gene (Atg) 7 or 5 in vitro and administration of 3-methyladenine (an autophagic inhibitor) in vivo disabled the inhibitory efficacy of LA on HBV DNA replication, suggesting that the anti-HBV efficacy of LA depended on its ability of inducing autophagy. LA could enhance lysosomal acidification and improve the function of lysosomes by promoting the protein expression of lysosomal-associated membrane protein (LAMP)-1, LAMP-2, and mature cathepsin D, which may contribute to the autophagic induction of LA. LA inhibited the activation of AKT and mammalian target of rapamycin (mTOR) induced by HBV, which was reversed by IGF-1 (an agonist of the PI3K/AKT/mTOR signaling pathway), indicating that LA elicited autophagy through hampering the PI3K/AKT/mTOR signaling pathway.
We revealed the anti-HBV activity and mechanism of LA in vitro and in vivo. This study facilitates a new understanding of the anti-HBV potent components of S. miltiorrhiza and sheds light on LA for further development as an active constituent or candidate used in the therapy against HBV infection.
丹参(丹参的根,在中国和其他一些亚洲国家,丹参被临床用于预防和治疗各种疾病,如心血管和脑血管疾病、糖尿病和乙型肝炎。丹参素(LA),一种源自丹参的多酚,据报道具有多种药理作用,如抗炎、抗 HIV 和抗四氯化碳诱导的肝损伤活性。然而,关于 LA 抗乙型肝炎病毒(HBV)的活性知之甚少。
本研究旨在研究 LA 在体外(HepG2.2.15 和 pHBV1.3 转染的 HepG2 细胞)和体内(pAAV-HBV1.2 水动力注射[HBV-HDI]小鼠)抗 HBV 的活性,并探讨其潜在机制。
通过酶联免疫吸附试验试剂盒检测乙型肝炎表面抗原(HBsAg)和乙型肝炎 e 抗原(HBeAg)含量。通过定量实时聚合酶链反应和免疫组织化学检测 HBV DNA 和乙型肝炎核心抗原(HBcAg)水平。通过 Western blot 检测自噬过程、溶酶体酸性功能和自噬相关信号通路中的蛋白。透射电子显微镜用于观察自噬体和自溶酶体的数量。共聚焦显微镜用于分析自噬流和溶酶体酸化,分别使用 mCherry-增强型绿色荧光蛋白(EGFP)-微管相关蛋白轻链(LC)3 和溶酶体探针。
LA 以剂量和时间依赖的方式抑制 HepG2.2.15 和 pHBV 转染的 HepG2 细胞中的 HBV DNA 复制,在一定程度上抑制 HepG2.2.15 细胞中的 HBsAg 和 HBeAg 水平,从而显示出抗 HBV 活性。LA 降低了 HBV-HDI C57BL/6 小鼠 3 周治疗期间血清/肝组织中的 HBV DNA、HBsAg/HBeAg 和 HBcAg 水平,并抑制了小鼠血清中 HBV DNA 和 HBsAg 的停药反弹。LA 在体外和体内增加 LC3-II 蛋白表达和自噬体/自噬体的数量,并促进自噬体 1(p62)蛋白的降解。LA 增强了 LC3 蛋白与自噬体的共定位,进一步证实了 LA 诱导完全自噬的能力。体外敲低自噬相关基因(Atg)7 或 5或体内给予 3-甲基腺嘌呤(自噬抑制剂)可削弱 LA 对 HBV DNA 复制的抑制作用,表明 LA 的抗 HBV 功效依赖于其诱导自噬的能力。LA 可通过促进溶酶体相关膜蛋白(LAMP)-1、LAMP-2 和成熟组织蛋白酶 D 的蛋白表达增强溶酶体酸化和改善溶酶体功能,这可能有助于 LA 诱导自噬。LA 抑制了 HBV 诱导的 AKT 和哺乳动物雷帕霉素靶蛋白(mTOR)的激活,IGF-1(PI3K/AKT/mTOR 信号通路的激动剂)可逆转这种激活,表明 LA 通过抑制 PI3K/AKT/mTOR 信号通路引发自噬。
我们在体外和体内揭示了 LA 的抗 HBV 活性和机制。本研究有助于深入了解丹参抗 HBV 的有效成分,并为进一步开发 LA 作为治疗乙型肝炎感染的活性成分或候选药物提供了思路。